Psyence Group Announces Closing Of Second Tranche Of Private Placement And Appointment Of Strategic Advisor
Psyence Group Announces Closing Of Second Tranche Of Private [...]
GOODMIND Available For Sale In The United Kingdom And Europe – Exclusive Distribution Agreement Concluded With This Works.
Psyence is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), entered into an exclusive distribution agreement with This Works Products Limited (“This Works”) for the distribution and sale of the joint venture’s functional mushroom brand, GOODMINDTM, in the United Kingdom and Europe.
Psyence Group Announces Strategic Private Placement
Psyence announce that it has received subscription agreements for gross proceeds of CAD$1.22 million from a consortium led by Brandon Kerzner, a member of the globally recognised Kerzner family. Brandon has a focus on investing in technology and life science advancement industries.
Psyence Group Completes Export Of Psilocybin Mushrooms to Portugal
Psyence Group is pleased to announce that it has successfully exported medical grade psilocybin mushrooms to Psilo Pharma Inc
Psyence Group Completes Export of Psilocybin Mushrooms to Canada
Psyence has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary of Filament Health Corp., is an exclusively natural psychedelic drug discovery and extraction company.
Psyence receives MHRA approval for Phase 2 trial
Psyence Group (“Psyence”) has announced formal approval from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) to commence their highly anticipated Phase 2 trial.
Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Psyence has partnered with a leading psychedelic Contract Research Organisation (CRO), Clerkenwell Health, to design and deliver the clinical trial. Clerkenwell has experience in conducting psychedelic research and the trial will be conducted at two centers in the United Kingdom.
Hannam & Partners Independent Research Report
Hannam & Partners issued an independent research report on Psyence identifying it as a first mover into the palliative care market supported by natural psilocybin production.
Psyence Group Announces Amendment and Closing of Previously Announced Private Placement
We are pleased to announce, further to the Company’s press release dated December 2, 2021, the amendment and closing of its first tranche of the previously announced non-brokered private placement offering (the “Private Placement”) raising gross process of $1.273 million.
Psyence Group Corporate Update
Psyence Group Corporate Update